Posted by Michael Wonder on 11 Nov 2022
Implementation of the Patented Medicine Prices Review Board's proposed Guidelines will harm Canadian patients
10 November 2022 - Innovative Medicines Canada is calling on Health Canada to direct the Patented Medicine Prices Review Board (PMPRB) to suspend its current Guidelines consultation process.
If the PMPRB's revised draft Guidelines are implemented without substantial changes as planned for the beginning of 2023, Canadian patients will be deprived of potentially life-saving new medicines.
